Clinical usefulness of the ovarian malignancy algorithm for diagnosing ovarian cancer
Abstract
Introduction: Ovarian cancer is the third most common gynecologic malignancy and has the worst prognosis. Less than 50 % of patients survive more than five years and 75 % are diagnosed when the disease is in advanced stages.
Objective: To describe the clinical usefulness of the ovarian malignancy algorithm in the diagnosis of ovarian cancer.
Methods: A literature review was carried out during the period from April 2021 to June 2021. A search of articles in English and Spanish was carried out in the PubMed and SciELO databases.
Development: The use of the tumor markers CA 125 and HE4 allows to estimate the risk of ovarian cancer in women with a pelvic mass, since it significantly improves the capability to identify pre- and postmenopausal women with high or low probability of ovarian cancer.
Conclusions: This algorithm is one of the best predictors for diagnosing ovarian cancer and for differentiating it from benign pelvic masses. It is important to note that such algorithm does not intend to replace complementary diagnostic procedures.
Keywords: ovarian neoplasms; biomarkers; diagnosis.
Downloads
References
REFERENCIAS BIBLIOGRÁFICAS
1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International Journal of Women’s Health. 2019. [citado 20 de Abr 2021]; 11(3):287–99. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500433/
2. Cuba. Ministerio de Salud Pública. Anuario Estadístico 2019 [Internet]. La Habana: MINSAP; 2020. [citado? 20 de Abr 2021];? [aprox 3p.]. Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electrónico-Español-2019-ed-2020.pdf
3. Kasper LD, Fauc AS, Hauser LS, Longo LD, Jameson JL, Loscalzo J. Harrison: Principios de Medicina Interna.19na ed. México, D.F: McGraw-Hill Interamerican. 2016 [citado 20 de Abr 2021]. Disponible en: https://www.academia.edu/40121481/P_R_I_N_C_I_P_I_O_S_H_A_R_R_I_S_O_N_H_A_R_ _I_S_O_N
4. Cabrera J, Franco J Calderaro Di R, Sunangela Escalona B, Roberto Carrillo, Heribert Saez R. Correlación de biomarcadores (HE4 Y CA-125), clínica, imaginología e histología en cáncer de ovario. Servicio Oncológico Hospitalario, Caracas, Venezuela. Rev Venez Oncol. 2015. [citado 20 de Abr 2021]; 27 (4): 207- 17 Disponible en: http://www.redalyc.org/articulo.oa?id=375641011003
5. Chyke A, Doubeni R, Myers A. Diagnosis and Management of Ovarian Cancer. AAFP. 2016. [citado 20 de Abr 2021]; 93(11):937-44. Disponible en: https://www.aafp.org/afp/2016/0601/p937.html
6. Forstner R, Meissnitzer M, Cunha T. Update on Imaging of Ovarian Cancer. Current Radiology Reports. 2016. [citado 20 de Abr 2021]; 4(6): 1-13. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826654/
7. US Preventive Task Force. Screening for Ovarian Cancer US Preventive Services Task Force Recommendation Statement. JAMA. 2018. [citado 20 de Abr 2021]; 319(12):588-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29450531/
8. Javadi S, Ganeshan D, Qayyum A, Iyer R, Bhosale P. Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. American Journal of Roentgenology. 2016. [citado 20 de Abr 2021]; 206(6):1351-60. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27042752/
9. Yang W-L, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017. [citado 20 de Abr 2021]; 17(3):5 77– 91. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28468520/
10. Yanaranop M, Anakrat V, Siricharoenthai S, et al. Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses? Gynecol Obstet Investig. 2017. [citado 20 de Abr 2021]; 82(11):47– 53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27197526/
11. Romagnolo C, Leon AE, Fabricio ASC, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol. 2016. [citado 20 de Abr 2021]; 141(1):303–11. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26801941/
12. Fortner RT, Vitonis AF, Schock H, et al. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. J Ovarian Res. 2017. [citado 20 de Abr 2021]; 10(2):19-20. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28320479/
13. Hermida Lazcano I, Sánchez Tejero E, Nerín Sánchez C, Cordero Bernabé R, Mora Escudero I, Pinar Sánchez J. Marcadores Tumorales. Rev Clin Med Fam. 2016. [citado 20 de Abr 2021]; 9(1):31- 42. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699- 695X2016000100006.
14. Lavín de Juan L. Marcadores Tumorales: Presente y Futuro. [Tesis]. [España]: Universidad Complutense; 2015. 22 p. [citado 20 de Abr 2021]. Disponible en: https://eprints.ucm.es/id/eprint/48763/1/LAURA%20LAVIN%20DE%20JUAN%20(1).pdf
15. Tahmasebi F, Nath R, Sokolovsky N, Scaoli J, Boley J, Mehra G, et al. Incidental Finding of Raised CA125: a Cause for Concern. Crit Care ObstGyne. 2018. [citado 20 de Abr 2021]; 5(1):3. Disponible en: https://obstetrics.imedpub.com/incidental-finding-of-raised-ca125-a-cause-forconcern.php?aid=23936
16. Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumors markers in 458 patients with ovarian tumors: diasnostic value of the combined use of HE4, CA125, CA19-9 and CEA in ovarian tumors. Cancer Manag Res. 2018 [citado 20 de Abr 2021]; 10: 1313-1318. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968799/
17. Noya Chaveco ME, Moya González NL, Llamos Sierra N, Morales Larramendi R, Cardona Garbey DL, Filiú Ferrera JL, et al. Roca Goderich: Temas de Medicina interna. 5ta ed. La Habana: Ciencias Médicas; 2017, pp 91- 110.
18. Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR. Current clinical aplication of serum biomarkers to detect ovarian cancer. Prz Menopauzalny. 2015 [citado 20 de Abr 2021]; 14(4):254-259. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733894/
19. Goff BA, Agnew K, Neradilek MB, Gray HJ, Liao JB, Urban RR. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol. Oncol. 2017. [citado 20 de Abr 2021]; 147(3) 291–5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28860006/
20. Dochez V, Randet M, Renaudeau C, Dimet J, Le Thuaut A, Winer N, et al. Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial. J ClinMed. 2019. [citado 20 de Abr 2021]; 25; 8(11): 83-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31699959/
21. Romagnolo C, Leon E, Fabricio A, Taborelli M, Polesel L, Steffan A, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol. Oncol. 2016. [citado 20 de Abr 2021]; 141(3), 303–11. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26801941/
22. Meys E, Kaijser J, Kruitwagen R, Slangen B, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur. J. Cancer. 2016. [citado 20 de Abr 2021]; 58(1)17–29. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26922169/
23. Núñez Nájera M, Morey León G, Nicola Salas E, Vega Luzuriaga P. Utilidad de la proteína epididimal humana 4 (HE4) en la detección del Cáncer de ovario. Rev. Oncol. Ecu. 2018. [citado 20 de Abr 2021]; 28(1): 22-33. Disponible en: http://fi-admin.bvsalud.org/document/view/9we9e
24. Jandow J, Rainczuk A, Infusini G, Makanji M, Bilandzic M, Wilson A. Discovery and validation of novel protein biomarkers in ovarian cancer patient urine. Proteomics–ClinicalApplications. 2018. [citado 20 de Abr 2021]; 12(3):17-35. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29426060/
25. Jia M, Deng J, Cheng X, Yan Z, Li Q, Xing Y. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget. 2017. [citado 20 de Abr 2021]; 8(6):96-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354761/
26. Lee S, Choi S, Lee Y, Chung D, Hong S, Park N. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2017. [citado 20 de Abr 2021]; 43(1):220-7. Disponible en: https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/jog.13181
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
